Socioeconomic status affects timing and duration of arthritis treatment

A recent study published in the Annals of the Rheumatic Diseases sheds light on the disparities in the treatment and management of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) among patients residing in different European countries. The study, initiated by the European Spondyloarthritis Research Collaboration Network (EuroSpA), aimed to investigate the relationship between patients' countries of residence and the severity of their conditions, as well as the timing and duration of advanced treatment. The findings suggest a notable difference in the treatment patterns of patients from wealthier European countries compared to those from middle- and low-income countries.

According to the study, patients from wealthier European countries tend to initiate biologic treatment earlier, which is a more advanced and typically more expensive therapeutic option. However, these patients also exhibit a higher likelihood of stopping or switching treatment earlier, which may be attributed to various factors, including cost concerns or differing healthcare systems. Conversely, patients from middle- and low-income countries tend to experience higher disease activity at the start of treatment, which may necessitate longer treatment durations and more frequent adjustments. This discrepancy highlights the need for equitable access to advanced treatment options and standardized care protocols across European countries.

The study's findings underscore the importance of addressing healthcare disparities and ensuring that patients from all socioeconomic backgrounds receive consistent and effective treatment for their conditions. By understanding these differences, healthcare providers and policymakers can work towards developing more inclusive and comprehensive treatment strategies that cater to the diverse needs of patients across Europe.